Company
CNTX +5.18%Context Therapeutics Inc.
Market Cap: $53.5 Million
USD as of Aug 2, 2026
$CNTX +5.18% $CNTX United States Healthcare Biotechnology US Healthcare US BiotechnologyCompany Description
Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of significant unmet medical need. Context Therapeutics operates within the life sciences and biotechnology sectors, engaging in research and development to combat cancers like breast and ovarian cancer. The company's approach involves optimizing therapeutic outcomes through cutting-edge research, clinical trials, and strategic collaborations. With a strong commitment to patient-centered care, Context Therapeutics impacts the healthcare industry by striving to provide more effective and personalized treatment options for female cancer patients. Established in an era of increased focus on women's health, Context Therapeutics plays a vital role in the continued evolution and enhancement of oncology treatment solutions in the financial market.
Context Therapeutics Inc. Market Capitalization Over Time
View HistoryEvolution of Context Therapeutics Inc. market cap in the past 5 years
Market capitalizations are calculated from the opening stock price at the beginning of each month.
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $209.25 B |
| Vertex Pharmaceuticals | $121.09 B |
| Regeneron Pharmaceuticals | $78.52 B |
| argenx | $52.93 B |
| Beigene Ltd. | $51.33 B |
Sector: Healthcare
| Company | Market Cap (USD) |
|---|---|
| Lilly | $1.024 T |
| Johnson & Johnson | $617.78 B |
| AbbVie | $443.36 B |
| Roche | $418.93 B |
| UnitedHealth Group | $376.34 B |
Detailed Description
Context Therapeutics Inc. is a biopharmaceutical company focused on advancing treatments for hormone-driven female cancers. Primarily, the company develops investigational therapies targeting estrogen receptors, aiming to innovate in areas of significant unmet medical need. Context Therapeutics operates within the life sciences and biotechnology sectors, engaging in research and development to combat cancers like breast and ovarian cancer. The company's approach involves optimizing therapeutic outcomes through cutting-edge research, clinical trials, and strategic collaborations. With a strong commitment to patient-centered care, Context Therapeutics impacts the healthcare industry by striving to provide more effective and personalized treatment options for female cancer patients. Established in an era of increased focus on women's health, Context Therapeutics plays a vital role in the continued evolution and enhancement of oncology treatment solutions in the financial market.
Financials
| Last Financial Reports Date | March 31, 2026 |
| Revenue TTM | $0 |
| EBITDA | $-43,500,404 |
| Gross Profit TTM | $0 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Quarterly Revenue Growth | % |
Stocks & Indexes
Context Therapeutics Inc. main stocks and indexes inclusions.
$CNTXRussell 2000 Russell 3000